Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone

BACKGROUND: To assess the efficacies and potential predictors of a corticosteroid switch in metastatic castration-resistant prostate cancer (mCRPC) patients with biochemical progression on abiraterone acetate plus prednisone (A + P). METHODS: Patients with mCRPC treated between April 2016 and August...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhenyu, Ni, Yuchao, Zhao, Diwei, Zhang, Yijun, Wang, Jun, Jiang, Lijuan, Chen, Dong, Wu, Zhiming, Wang, Yanjun, He, Liru, Shi, Yanxia, Zhou, Fangjian, Zeng, Hao, Li, Yonghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364094/
https://www.ncbi.nlm.nih.gov/pubmed/34388965
http://dx.doi.org/10.1186/s12885-021-08670-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364094/
https://www.ncbi.nlm.nih.gov/pubmed/34388965
http://dx.doi.org/10.1186/s12885-021-08670-2

Ejemplares similares